Recent Finacing
Recent Raise
Aptadir develops a preclinical DiR RNA-inhibitor platform to generate gene-targeted DNMT inhibitors that reactivate hypermethylated genes for cancer and genetic disorders, with a lead MDS program.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Aptadir Therapeutics.
